OmiCure Publication

OmiCure and Ariana Pharma today announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were displayed at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have the potential to expand personalized cancer treatment options for patients with advanced & refractory diseases.

The next frontier in precision oncology sits at the intersection of transcriptomics (RNA sequencing), AI technology, and the multiple global validated data sources of existing therapies and clinical trials. As evidenced in the WINTHER trial (Nature Med, April 2019), RNA analysis surfaces actionable data and gives patients and their oncologists the tools to make better treatment decisions about advanced cancers whose biomarkers are hiding in plain sight. This article presents six cases studies from the WINTHER clinical trial to illustrate the power of this new approach to treatment decision-making.

Cancer scientists are going beyond DNA to study RNA and the transcriptome. A recent Omicure et al. article in the Journal of Clinical Colorectal Cancer highlights how RNA sequencing is revealing further characteristics of cancer than those known via DNA. This can potentially lead to additional therapeutic options, particularly once treatment resistance has set in.